Browse

Effectiveness and tolerability of long-acting risperidone: A 9-month open-label extension of a 12-week switching study from oral antipsychotics

DC Field Value Language
dc.contributor.authorKim, Chang Yoon-
dc.contributor.authorChung, Seockhoon-
dc.contributor.authorHahm, Bong-Jin-
dc.contributor.authorHong, Kyung Sue-
dc.contributor.authorKim, Young-Hoon-
dc.contributor.authorLee, Sang-Yeol-
dc.contributor.authorChung, In-Won-
dc.contributor.authorKim, Chan-Hyung-
dc.contributor.authorLee, Yanghyun-
dc.contributor.authorBahk, Won-Myong-
dc.contributor.authorYoon, Jin-Sang-
dc.date.accessioned2012-07-04T08:59:26Z-
dc.date.available2012-07-04T08:59:26Z-
dc.date.issued2009-
dc.identifier.citationINTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE; Vol.13(3); 192-198ko_KR
dc.identifier.issn1365-1501-
dc.identifier.urihttps://hdl.handle.net/10371/78495-
dc.description.abstractObjectives. The aim of this non-randomized, single-arm, multi-center, 9-month extension study was to evaluate the maintained efficacy and tolerability of long-acting risperidone injection when we switched to it from previous oral antipsychotics in symptomatically stable patients with schizophrenia or other psychotic disorders. Methods. A total of 98 patients who had completed a previous 12-week acute phase study were included. Efficacy and tolerability were assessed with the Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression (CGI), Global Assessment of Functioning (GAF), and Extrapyramidal Symptom Rating Scale (ESRS). Results. The remission rate of 77.6% (76/98) at baseline and 57.1% (56/98) at the end of the study. Of patients who were in remission at baseline, 65.8% (50/76) maintained their remission state until the end. The symptom worsening rate was relatively low (11.1%), and there was no aggravation in mean PANSS total and subscale scores. Spontaneous treatment-emergent adverse events (TEAE) were reported by 21 (21.4%) patients, and most commonly reported adverse events were extrapyramidal symptoms (N=6, 6.1%) and insomnia (N=4, 4.1%). Extrapyramidal symptoms were significantly improved. Conclusions. Switching to long-acting risperidone injection from oral antipsychotics was a safe and well-tolerated strategy for maintaining clinical stability in symptomatically stable patients with schizophrenia.ko_KR
dc.language.isoenko_KR
dc.publisherInforma Healthcareko_KR
dc.subjectLong-acting injectionko_KR
dc.subjectrisperidoneko_KR
dc.subjectmaintenanceko_KR
dc.subjectremissionko_KR
dc.titleEffectiveness and tolerability of long-acting risperidone: A 9-month open-label extension of a 12-week switching study from oral antipsychoticsko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor김창윤-
dc.contributor.AlternativeAuthor정석훈-
dc.contributor.AlternativeAuthor함봉진-
dc.contributor.AlternativeAuthor홍경수-
dc.contributor.AlternativeAuthor윤진상-
dc.contributor.AlternativeAuthor김영훈-
dc.contributor.AlternativeAuthor박원명-
dc.contributor.AlternativeAuthor이상열-
dc.contributor.AlternativeAuthor이양현-
dc.contributor.AlternativeAuthor정인원-
dc.contributor.AlternativeAuthor김찬형-
dc.identifier.doi10.1080/13651500902737000-
dc.citation.journaltitleINTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE-
dc.description.citedreferencevan Os J, 2006, ACTA PSYCHIAT SCAND, V113, P91, DOI 10.1111/j.1600-0447.2005.00659.x-
dc.description.citedreferenceSethuraman G, 2005, SCHIZOPHR RES, V79, P337, DOI 10.1016/j.schres.2005.06.015-
dc.description.citedreferenceLasser RA, 2005, SCHIZOPHR RES, V77, P215, DOI 10.1016/j.schres.2005.03.006-
dc.description.citedreferenceGastpar M, 2005, J PSYCHOPHARMACOL, V19, P32, DOI 10.1177/0269881105056598-
dc.description.citedreferenceParellada E, 2005, J PSYCHOPHARMACOL, V19, P5, DOI 10.1177/0269881105056513-
dc.description.citedreferenceChouinard G, 2005, SCHIZOPHR RES, V76, P247, DOI 10.1016/j.schres.2005.02.013-
dc.description.citedreferenceAndreasen NC, 2005, AM J PSYCHIAT, V162, P441-
dc.description.citedreferenceCHUNG S, 2005, KOREAN J PSYCHOPHARM, V16, P109-
dc.description.citedreferenceLindenmayer JP, 2004, J CLIN PSYCHIAT, V65, P1084-
dc.description.citedreferencevan Os J, 2004, INT CLIN PSYCHOPHARM, V19, P229, DOI 10.1097/01.yic.0000122861.35081.16-
dc.description.citedreferenceCorrell CU, 2004, AM J PSYCHIAT, V161, P414-
dc.description.citedreferenceLehman AF, 2004, AM J PSYCHIAT, V161, P1-
dc.description.citedreferenceHarrison TS, 2004, CNS DRUGS, V18, P113-
dc.description.citedreferenceBeasley CM, 2003, J CLIN PSYCHOPHARM, V23, P582, DOI 10.1097/01.jcp.0000095348.32154.ec-
dc.description.citedreferenceFleischhacker WW, 2003, J CLIN PSYCHIAT, V64, P1250-
dc.description.citedreferenceLieberman JA, 2003, NEUROPSYCHOPHARMACOL, V28, P995, DOI 10.1038/sj.npp.1300157-
dc.description.citedreferenceKane JM, 2003, J CLIN PSYCHIAT, V64, P19-
dc.description.citedreferenceKane JM, 2003, J CLIN PSYCHIAT, V64, P34-
dc.description.citedreferenceRobinson DG, 2002, SCHIZOPHR RES, V57, P209-
dc.description.citedreferenceCsernansky JG, 2002, NEW ENGL J MED, V346, P16-
dc.description.citedreferenceDolder CR, 2002, AM J PSYCHIAT, V159, P103-
dc.description.citedreferenceGitlin M, 2001, AM J PSYCHIAT, V158, P1835-
dc.description.citedreferenceKANE G, 1999, YEARB LANGL, V13, P7-
dc.description.citedreferenceKane JM, 1998, EUR NEUROPSYCHOPHARM, V8, P55-
dc.description.citedreferenceDAVIS JM, 1994, DRUGS, V47, P741-
dc.description.citedreferenceHOGAN TP, 1992, PSYCHOL MED, V22, P347-
dc.description.citedreferenceWARE JE, 1988, MED CARE, V26, P393-
dc.description.citedreferenceERESHEFSKY L, 1984, J CLIN PSYCHIAT, V45, P50-
dc.description.citedreferenceDAVIS JM, 1975, AM J PSYCHIAT, V132, P1237-
dc.description.tc0-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Psychiatry (정신과학전공)Journal Papers (저널논문_정신과학전공)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse